MORE►
Duchenne muscular dystrophy
Secretome Therapeutics’ leadership team includes, from left: David Chapman, senior vice president of operations; Karin Lucas, Ph.D., vice president of medical affairs; Maggie Loeffler, CPA, vice president of finance and administration; and Marshelle Smith, M.D., chief development officer. [Photos: Secretome Therapeutics]
Secretome Therapeutics Builds Out Rare Disease Leadership Team
by Sandra Engelland | Aug 4, 2026
The Plano company’s lead candidate uses neonatal cardiac progenitor cells to target the heart complications of Duchenne muscular dystrophy.
by Lance Murray |
Sep 9, 2025
Eric Olson has spent decades dedicated to what he calls “the biggest prize of all”: a cure for the devastating disease. Nearly half of the scientists awarded Columbia’s Horwitz Prize over the past 58 years went on to win a Nobel, UTSW said.
MORE►
by Lance Murray |
Jun 17, 2019
The biotech company uses CRISPR technology licensed from UT Southwestern Medical Center in Dallas, and was co-founded by UTSW researcher and faculty member Eric Olson.
MORE►
by Lance Murray |
Sep 7, 2018
Also, you'll learn about advances to treat Duchenne muscular dystrophy and migraines. Here are some of the research projects underway in North Texas that could make lives better.
MORE►
